These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21109842)

  • 41. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP2D6 phenotype prediction from genotype: which system is the best?
    Kirchheiner J
    Clin Pharmacol Ther; 2008 Feb; 83(2):225-7. PubMed ID: 18202689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice.
    Dunbar L; Butler R; Wheeler A; Pulford J; Miles W; Sheridan J
    J Psychopharmacol; 2012 Mar; 26(3):390-7. PubMed ID: 19942639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Have we successfully implemented CYP2D6 genotyping in psychiatry?
    de Leon J
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1201-1203. PubMed ID: 29164956
    [No Abstract]   [Full Text] [Related]  

  • 48. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics.
    Hinrichs JW; Loovers HM; Scholten B; van der Weide J
    Eur J Clin Pharmacol; 2008 Oct; 64(10):979-86. PubMed ID: 18553077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
    Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML
    Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice.
    Mrazek DA
    CNS Spectr; 2006 Mar; 11(3 Suppl 3):3-4. PubMed ID: 17760222
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
    Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
    Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.
    de Leon J; Barnhill J; Rogers T; Boyle J; Chou WH; Wedlund PJ
    Am J Psychiatry; 1998 Sep; 155(9):1278-80. PubMed ID: 9734555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.
    Maier W; Zobel A
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():12-20. PubMed ID: 18344045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6.
    Sánchez-Martín A; Sánchez-Iglesias S; García-Berrocal B; Lorenzo C; Gaedigk A; Isidoro-García M
    Pharmacogenomics; 2016 Aug; 17(12):1291-3. PubMed ID: 27469479
    [No Abstract]   [Full Text] [Related]  

  • 59. [Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].
    Suzuki Y; Sawamura H; Someya T
    Seishin Shinkeigaku Zasshi; 2006; 108(6):633-41. PubMed ID: 16910543
    [No Abstract]   [Full Text] [Related]  

  • 60. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
    Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T
    Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.